Management of acute submacular XXXX using recombinant tissue plasminogen activator and gas.

@entity1 @entity548 @entity1713 @entity2435 @entity1020
PURPOSE: To assess the effects of intravitreal injection of recombinant tissue plasminogen activator ( @entity2435 ) and gas on submacular @entity548 in @entity1020 ( @entity1020 ). METHODS: Eleven consecutive @entity1 (11 eyes) with @entity548 due to @entity1020 involving the fovea with elevation of the neurosensory retina were included in this study. @entity548 occured 12 h to 14 days before onset of therapy. Injection of @entity2435 through the pars plana in a dose of 50 or 100 microg was performed. Gas instillation (0.2-0.4 ml) followed @entity2435 injection, either immediately after injection (7 @entity1 ) or during the following day (4 @entity1 ). RESULTS: After intravitreal injection of @entity2435 , subretinal clots were totally or partially liquefied when treatment started up to 3 days after onset of @entity548 . In all @entity1 treated with 100 microg @entity2435 a large exudative @entity1713 resulted, which reabsorbed spontaneously within 2 weeks. After reattachment of the exudative retinal @entity1713 of the retinal pigment epithelium was noted. Temporary opacification of the vitreous was observed between the 2nd and 7th postoperative day in 5 eyes (45.5%). Postoperative visual acuity increased in 5 @entity1 (45.5%). CONCLUSION: Intravitreal application of @entity2435 followed by gas injection is a sufficient and convenient technique for effective removal of freshly formed submacular @entity548 . Removal is mediated through combined enzymatic ( @entity2435 ) and mechanical (gas) effects. This technique offers a quick recovery of vision in eyes with less severe @entity1020 .
